title: [Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors].
abstract: The higher the low-density-lipoprotein cholesterol (beta lipoprotein) level, the greater the risk that coronary heart disease will develop, alpha-lipoprotein fractions (high-density-lipoproteins) are considered to be protective factors. Medroxyprogesterone acetate is responsible for characteristic changes of the lipoprotein patterns indicating enhanced coronary risks. Medroxyprogesterone acetate is applied in the therapy of breast, uterus and ovarian cancer. A statistically significant decrease was observed in alpha-lipoproteins whereas beta-lipoproteins increased without statistical significance. A similar reaction can be observed under the combination therapy of aminoglutethimide and medroxyprogesterone acetate, whereas the combination of cortisone and aminoglutethimide has a distinct influence on beta-lipoproteins but the alpha-lipoprotein level remains uninfluenced. According to these data the effect of an adjuvant application of these drugs must be carefully evaluated due to an increase of coronary risks.
authors.forename: H E
authors.initials: HE
authors.lastname: Wander
authors.forename: A T
authors.initials: AT
authors.lastname: Teichmann
authors.forename: P
authors.initials: P
authors.lastname: Cremer
authors.forename: H
authors.initials: H
authors.lastname: Wieland
authors.forename: B
authors.initials: B
authors.lastname: Kruse
authors.forename: G A
authors.initials: GA
authors.lastname: Nagel
authors.forename: W
authors.initials: W
authors.lastname: Kuhn
authors.forename: D
authors.initials: D
authors.lastname: Seidel
mesh_terms: D000616:Aminoglutethimide / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D003348:Cortisone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008593:Menopause; D009362:Neoplasm Metastasis; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000188:drug therapy*; D014280:Triglycerides / Q000097:blood
chemical_list: D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D000616:Aminoglutethimide; D002784:Cholesterol; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D003348:Cortisone
vernacular_title: Veränderungen der Serumlipoproteine unter hormonellen Therapieformen des Mammakarzinoms und anderer endokrin abhängiger Tumoren.